Revvity’s third quarter results were met with a significant negative reaction from the market, as investors focused on sluggish organic revenue growth and margin compression despite headline results aligning with Wall Street expectations. Management pointed to a strong performance in its Signals software and reproductive health businesses, with CEO Prahlad R. Singh highlighting that “our signals software business continued to perform extremely well, growing 20% organically,” and that “newborn screening again grew in the high single digits in the quarter.” However, challenges persisted, particularly in China’s diagnostics segment, where volumes remained under pressure, and lower life sciences reagent sales contributed to margin declines. Singh acknowledged these headwinds, noting the company remains focused on cost containment and cash flow generation.
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.2% year on year to $698.9 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.86 billion at the midpoint. Its non-GAAP profit of $1.18 per share was 3.6% above analysts’ consensus estimates.
Shares of life sciences company Revvity (NYSE:RVTY)
fell 2.4% in the afternoon session after it reported third-quarter financial results that showed a drop in profits and margins, even as revenue grew.
Wall Street extended its record-setting streak on Monday, with major large-cap indices logging a third consecutive session of strong gains after a breakthrough in trade negotiations between Washington and Beijing.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.2% year on year to $698.9 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.86 billion at the midpoint. Its non-GAAP profit of $1.18 per share was 3.6% above analysts’ consensus estimates.
The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at research tools & consumables stocks, starting with Revvity (NYSE:RVTY).
Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company’s sustainability, social and governance strategy, initiatives and performance. This year’s report, Progress with Purpose: Science and Sustainability, highlights the Company’s strengthened partnerships, product innovation, sustainability driven investments and other efforts aimed at advancing science and human health responsibly.
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before the close of 2025. This aggressive stance comes on the heels of a September rate reduction and is primarily driven
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
